The web Browser you are currently using is unsupported, and some features of this site may not work as intended. Please update to a modern browser such as Chrome, Firefox or Edge to experience all features Michigan.gov has to offer.
Mpox Resources for Health Care Professionals
Handout for those exposed – give to confirmed mpox cases to share with close contacts
For more information or for questions, please contact your local health department. If you need additional information, contact MDHHS Communicable Disease at 517-335-8165.
JYNNEOS Operational Guide Updated 11-2-2022
Tecovirimat (TPOXX) may be considered for treatment in people infected with mpox virus.
Prior to ordering, review the TPOXX Request Procedure for eligibility criteria.
- To request TPOXX for a patient, contact the local health department (LHD). When product is available, requester and the LHD will arrange delivery of product locally.
- If the local health department is unable to provide TPOXX, then it should be requested from MDHHS through the TPOXX Request Form. This form will solicit needed doses and provide required deidentified patient and provider information. Receipt of the form will be monitored, and approved orders will be supplied within 24 hours after receipt Monday - Friday.
Clinicians can contact the CDC Mpox Clinical Team to request clinical consults regarding treatment, management, etc.
- Non-urgent inquires: Submit the request by emailing firstname.lastname@example.org.
- Urgent inquiries: Call the CDC Emergency Operations Center at 770-488-7100.
View TPOXX Request Procedure for additional information.
Mpox Program Provider Guidance
MDHHS Mpox Program Provider Addendum Updated 12-19-2022
Mpox Vaccine and Therapeutics Provider Considerations for Approval Updated 10-25-2022
JYNNEOS Vaccine Update - August 26, 2022
Increased Commercial Laboratory Capacity for Mpox
MDHHS Bureau of Laboratories (BOL) has the capability to test for orthopoxvirus as the first step in identifying mpox infection. As the need for testing increases, MDHHS is asking that health care providers consider utilizing recently onboarded commercial laboratories to expand testing capacity. This will increase accessibility for patients and health care providers and prevent delays in turnaround times. On June 22, 2022, the Department of Health and Human Services (HHS) announced that Mpox testing capacity would be expanded to five commercial laboratory companies. Currently, the laboratories that can perform orthopoxvirus testing include Aegis Science, Labcorp, Mayo Clinic Laboratories, Quest Diagnostics, and Sonic Healthcare. Onboarding of new laboratories is an evolving environment—check here for any new labs added: What’s New & Updated | Mpox | CDC.
MDHHS has ensured that positive results from MDHHS BOL and the commercial laboratories will be reported into the Michigan Disease Surveillance System (MDSS) via electronic laboratory reporting (ELR). Mpox cases in the MDSS are currently being classified as an “Unusual Outbreak or Occurrence” until a mpox disease-specific form is finalized.
CDC Preparation and Collection of Specimens
Preparation and Collection of Specimens | Mpox | CDC
- Instructions for specimen collection are found in Investigation of Suspect Cases of Mpox.
- Please collect a maximum of six swabs (two swabs from each of three sites), preferably lesions that are vesicles, pustules, or scabs. A single site or two sites is preferred.
- Providers may want to continue to consider testing at MDHHS BOL for individuals who are uninsured/underinsured where commercial testing cost may be a burden.
Statewide, local health departments and clinical partners have reported 14,346 total administrations of JYNNEOS vaccine to the Michigan Care Improvement Registry (MCIR) through Monday, March 13, 2023.
*Doses administered are reported by providers and can be subject to delays. Previously reported numbers may change as new reports are received. MDHHS pulls the data for cleaning and posts to the website bi-weekly every other Tuesday.